Skip to main content
. 2009 Jan 28;9:38. doi: 10.1186/1471-2407-9-38

Figure 2.

Figure 2

Median inhibition by zoledronic acid and fluvastatin alone and in combination in a) breast carcinomas tested with fluvastatin concentration A (n = 9); b) ovarian carcinomas tested with fluvastatin concentration A (n = 8) and c) ovarian carcinomas tested with fluvastatin concentration B (n = 14). The combination results are expressed as micromolar concentrations of zoledronic acid.